Results · Apr-Jun 2026
Transgene Biotek Q1 FY27 results
Sales grew 21% to ₹0.06 crore from ₹0.05 crore in Apr-Jun 2025.
Operating profit was −₹0.06 crore, an operating margin of −97.0% (up 182.6 points from a year ago).
The net loss narrowed to ₹0.39 crore from ₹0.43 crore.
Against Jan-Mar 2026: sales +10%, loss narrows.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 0.1 | 0.0 | +21% |
| Operating profit (EBITDA) | -0.1 | -0.1 | n/m |
| Operating margin | −97.0% | −279.6% | +182.6 pts |
| Net profit | -0.4 | -0.4 | loss narrows |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.